You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR SUBOXONE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for SUBOXONE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT00637000 ↗ Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone Completed Indivior Inc. Phase 2 2008-03-01 The purpose of this study is to compare the presence, degree, time course and profile of opioid withdrawal symptoms associated with induction onto new formulations of buprenorphine or buprenorphine/naloxone in persons with active opioid dependence. The primary outcome measure is the severity of withdrawal symptoms measured using the Clinical Opiate Withdrawal Scale (COWS). The primary study hypothesis is that neither drug formulation will precipitate an opioid withdrawal syndrome.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for SUBOXONE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000320 ↗ Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1 Completed National Institute on Drug Abuse (NIDA) Phase 1/Phase 2 1997-10-01 The purpose of this study is to compare subject response to liquid vs. tablet formulations, to assess bioequivalency of liquid vs. tablet, to compare subject preference, and to evaluate if dose response curve for tablet is equal to liquid form."
NCT00078117 ↗ Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1 Completed University of California, Los Angeles Phase 3 2003-06-01 The purpose of this protocol is to to compare the clinical utility of two dosage tapering regimens in Buprenorphine/Naloxone stabilized subjects for opiate detoxification.
NCT00249574 ↗ Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1 Completed Organization to Achieve Solutions in Substance Abuse (OASIS) N/A 2003-06-01 The purpose of this study is to see whether street-recruited heroin users can be successfully treated for hepatitis C after stabilizing them on buprenorphine.
NCT00249574 ↗ Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1 Completed National Institute on Drug Abuse (NIDA) N/A 2003-06-01 The purpose of this study is to see whether street-recruited heroin users can be successfully treated for hepatitis C after stabilizing them on buprenorphine.
NCT00367302 ↗ Buprenorphine Maintenance for Opioid-Addicted Persons in Jail and Post-Release Completed National Institute on Drug Abuse (NIDA) Phase 1/Phase 2 2006-08-01 The purpose of the study is to determine the feasibility of providing buprenorphine maintenance to opioid-dependent offenders in a jail setting and of transitioning those patients to buprenorphine maintenance in the community after their release.
NCT00367302 ↗ Buprenorphine Maintenance for Opioid-Addicted Persons in Jail and Post-Release Completed New York City Department of Health and Mental Hygiene Phase 1/Phase 2 2006-08-01 The purpose of the study is to determine the feasibility of providing buprenorphine maintenance to opioid-dependent offenders in a jail setting and of transitioning those patients to buprenorphine maintenance in the community after their release.
NCT00367302 ↗ Buprenorphine Maintenance for Opioid-Addicted Persons in Jail and Post-Release Completed Western Michigan University Phase 1/Phase 2 2006-08-01 The purpose of the study is to determine the feasibility of providing buprenorphine maintenance to opioid-dependent offenders in a jail setting and of transitioning those patients to buprenorphine maintenance in the community after their release.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SUBOXONE

Condition Name

Condition Name for SUBOXONE
Intervention Trials
Opioid Dependence 15
Opioid-Related Disorders 14
Opioid Use Disorder 12
Opioid-use Disorder 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for SUBOXONE
Intervention Trials
Opioid-Related Disorders 71
Substance-Related Disorders 23
Disease 12
Emergencies 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SUBOXONE

Trials by Country

Trials by Country for SUBOXONE
Location Trials
United States 239
Canada 9
Norway 5
Taiwan 3
Austria 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for SUBOXONE
Location Trials
New York 17
California 16
Florida 15
Maryland 14
Massachusetts 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SUBOXONE

Clinical Trial Phase

Clinical Trial Phase for SUBOXONE
Clinical Trial Phase Trials
Phase 4 30
Phase 3 21
Phase 2/Phase 3 4
[disabled in preview] 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for SUBOXONE
Clinical Trial Phase Trials
Completed 61
Recruiting 14
Not yet recruiting 9
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SUBOXONE

Sponsor Name

Sponsor Name for SUBOXONE
Sponsor Trials
National Institute on Drug Abuse (NIDA) 25
Indivior Inc. 19
Johns Hopkins University 7
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for SUBOXONE
Sponsor Trials
Other 126
Industry 46
NIH 27
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.